J&J Unit Revises Label For Evra Patch In Canada

Law360, New York (March 23, 2009, 12:00 AM EDT) -- Johnson & Johnson's Canadian subsidiary has updated labeling information for Evra, a birth control patch linked to blood clots, to state that the drug releases a greater amount of hormones on a daily basis than previously indicated.

Toronto-based Janssen-Ortho Inc. announced Thursday through Health Canada, the country's health care regulator, that it was changing the average daily release rates listed for the patch from 150 micrograms of norelgestromin, a progestin hormone, to 200 micrograms.

The figure listed for the amount of ethinyl estradiol, an estrogen hormone,...
To view the full article, register now.